Herbert Virgin - 22 Feb 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP, Research & CSO
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
22 Feb 2022
Net transactions value
-$39,146
Form type
4
Filing time
24 Feb 2022, 20:30:48 UTC
Previous filing
22 Feb 2022
Next filing
11 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +70,000 +66% $0.000000 175,407 22 Feb 2022 Direct F1
transaction VIR Common Stock Options Exercise $2,104 +1,375 +0.78% $1.53* 176,782 22 Feb 2022 Direct
transaction VIR Common Stock Sale $41,250 -1,375 -0.78% $30.00 175,407 22 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -1,375 -0.62% $0.000000 219,505 22 Feb 2022 Common Stock 1,375 $1.53 Direct F3
transaction VIR Stock Option (Right to Buy) Award $0 +70,000 $0.000000 70,000 22 Feb 2022 Common Stock 70,000 $29.48 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
F3 The option is fully vested and exercisable.
F4 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.